Works by Tolcher, A W

Results: 24

Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α<sub>5</sub>β<sub>1</sub> integrin monoclonal antibody (volociximab) in cancer patients.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 207, doi. 10.1007/s00280-009-1023-8

By:

Ng, Chee C.;
Bai, S.;
Takimoto, C. H.;
Tang, M. T.;
Tolcher, A. W.

Publication type:

Article

Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 65, n. 1, p. 167, doi. 10.1007/s00280-009-1020-y

By:

Chia-Chi Lin;
Beeram, Muralidhar;
Rowinsky, Eric K.;
Takimoto, Chris H.;
Ng, Chee M.;
Geyer Jr., Charles E.;
Denis, Louis J.;
De Bono, Johann S.;
Hao, Desiree;
Tolcher, Anthony W.;
Rha, Sun-Young;
Jolivet, Jacques;
Patnaik, Amita

Publication type:

Article

Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 6, p. 1065, doi. 10.1007/s00280-008-0811-x

By:

Chia-Chi Lin;
Calvo, Emiliano;
Papadopoulos, Kyriakos P.;
Patnaik, Amita;
Sarantopoulos, John;
Mita, Alain C.;
Preston, Glenn G.;
Mita, Monica M.;
Rodon, Jordi;
Mays, Theresa;
I.-Tien Yeh;
O'Rourke, Pat;
Takimoto, Chris H.;
Dancey, Janet E.;
Chen, Helen;
Tolcher, Anthony W.

Publication type:

Article

Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study.

Published in:

Cancer Chemotherapy & Pharmacology, 2008, v. 62, n. 5, p. 911, doi. 10.1007/s00280-007-0672-8

By:

Rodon, Jordi;
Garrison, Mitchell;
Hammond, Lisa A.;
de Bono, Johann;
Smith, Lon;
Forero, Leonardo;
Hao, Desirée;
Takimoto, Chris;
Lambert, John M.;
Pandite, Lini;
Howard, Maria;
Hongsheng Xie;
Tolcher, Anthony W.

Publication type:

Article

Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.

Published in:

Cancer Chemotherapy & Pharmacology, 2008, v. 62, n. 1, p. 97, doi. 10.1007/s00280-007-0579-4

By:

Guo, Feng;
Letrent, Stephen P.;
Munster, Pamela;
Britten, Carolyn D.;
Gelmon, Karen;
Tolcher, Anthony W.;
Sharma, Amarnath

Publication type:

Article

A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.

Published in:

Cancer Chemotherapy & Pharmacology, 2007, v. 59, n. 2, p. 165, doi. 10.1007/s00280-006-0255-0

By:

Mita, Monica M.;
Rowinsky, Eric K.;
Forero, Leonardo;
Eckhart, S. Gail;
Izbicka, Elzbieta;
Weiss, Geoffrey R.;
Beeram, Muralidhar;
Mita, Alain C.;
de Bono, Johann S.;
Tolcher, Anthony W.;
Hammond, Lisa A.;
Simmons, Paul;
Berg, Kristin;
Takimoto, Chris;
Patnaik, Amita

Publication type:

Article

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.

Published in:

2017

By:

Papadopoulos, K P;
El-Rayes, B F;
Tolcher, A W;
Patnaik, A;
Rasco, D W;
Harvey, R D;
LoRusso, P M;
Sachdev, J C;
Abbadessa, G;
Savage, R E;
Hall, T;
Schwartz, B;
Wang, Y;
Kazakin, J;
Shaib, W L

Publication type:

journal article

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.

Published in:

2017

By:

Bendell, Johanna C;
Javle, Milind;
Bekaii-Saab, Tanios S;
Finn, Richard S;
Wainberg, Zev A;
Laheru, Daniel A;
Weekes, Colin D;
Tan, Benjamin R;
Khan, Gazala N;
Zalupski, Mark M;
Infante, Jeffrey R;
Jones, Suzanne;
Papadopoulos, Kyriakos P;
Tolcher, Anthony W;
Chavira, Renae E;
Christy-Bittel, Janna L;
Barrett, Emma;
Patnaik, Amita

Publication type:

journal article

Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.

Published in:

2011

By:

Mita, A C;
Papadopoulos, K;
de Jonge, M J A;
Schwartz, G;
Verweij, J;
Mita, M M;
Ricart, A;
Chu, Q S-C;
Tolcher, A W;
Wood, L;
McCarthy, S;
Hamilton, M;
Iwata, K;
Wacker, B;
Witt, K;
Rowinsky, E K

Publication type:

journal article

Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.

Published in:

2018

By:

Goss, Glenwood D.;
Vokes, Everett E.;
Gordon, Michael S.;
Gandhi, Leena;
Papadopoulos, Kyriakos P.;
Rasco, Drew W.;
Fischer, JuDee S.;
Chu, Katharine L.;
Ames, William W.;
Mittapalli, Rajendar K.;
Lee, Ho‐Jin;
Zeng, Jiewei;
Roberts‐Rapp, Lisa A.;
Loberg, Lise I.;
Ansell, Peter J.;
Reilly, Edward B.;
Ocampo, Christopher J.;
Holen, Kyle D.;
Tolcher, Anthony W.;
Lee, Ho-Jin

Publication type:

journal article

PI-13.

Published in:

Clinical Pharmacology & Therapeutics, 2006, v. 79, n. 2, p. P10, doi. 10.1016/j.clpt.2005.12.034

By:

Guo, F.;
Letrent, S. P.;
Noe, D. A.;
Qin, A.;
Rohrbacher, K. D.;
Munster, P. N.;
Tolcher, A. W.;
Britten, C. D.;
Gelmon, K.;
Sharma, A.

Publication type:

Article

Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.

Published in:

2020

By:

Tolcher, Anthony W.;
Kurzrock, Razelle;
Valero, Vincente;
Gonzalez, Rene;
Heist, Rebecca S.;
Tan, Antoinette R.;
Means-Powell, Julie;
Werner, Theresa L.;
Becerra, Carlos;
Wang, Chenxi;
Leonowens, Cathrine;
Kalyana-Sundaram, Shanker;
Kleha, Joseph F.;
Gauvin, Jennifer;
D'Amelio, Anthony M.;
Ellis, Catherine;
Ibrahim, Nageatte;
Yan, Li;
D'Amelio, Anthony M Jr

Publication type:

journal article

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors.

Published in:

2017

By:

Tolcher, Anthony;
Berlin, Jordan;
Cosaert, Jan;
Kauh, John;
Chan, Emily;
Piha-Paul, Sarina;
Amaya, Alex;
Tang, Shande;
Driscoll, Kyla;
Kimbung, Richard;
Kambhampati, S.;
Gueorguieva, Ivelina;
Hong, David;
Tolcher, Anthony W;
Berlin, Jordan D;
Piha-Paul, Sarina A;
Kambhampati, S R Prasad;
Hong, David S

Publication type:

journal article

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.

Published in:

2015

By:

Tolcher, Anthony;
LoRusso, Patricia;
Arzt, Jennifer;
Busman, Todd;
Lian, Guinan;
Rudersdorf, Niki;
Vanderwal, Carol;
Kirschbrown, Whitney;
Holen, Kyle;
Rosen, Lee;
Tolcher, Anthony W;
Busman, Todd A;
Rudersdorf, Niki S;
Vanderwal, Carol Ann;
Holen, Kyle D;
Rosen, Lee S

Publication type:

journal article

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.

Published in:

2015

By:

Tolcher, Anthony;
LoRusso, Patricia;
Arzt, Jennifer;
Busman, Todd;
Lian, Guinan;
Rudersdorf, Niki;
Vanderwal, Carol;
Waring, Jeffrey;
Yang, Jianning;
Holen, Kyle;
Rosen, Lee;
Tolcher, Anthony W;
Busman, Todd A;
Rudersdorf, Niki S;
Vanderwal, Carol Ann;
Waring, Jeffrey F;
Holen, Kyle D;
Rosen, Lee S

Publication type:

journal article

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.

Published in:

Journal of Hematology & Oncology, 2014, v. 7, n. 1, p. 3, doi. 10.1186/1756-8722-7-1

By:

Rhoda Molife, L.;
Li Yan;
Vitfell-Rasmussen, Joanna;
Zernhelt, Adriane M.;
Sullivan, Daniel M.;
Cassier, Philippe A.;
Eric Chen;
Biondo, Andrea;
Tetteh, Ernestina;
Siu, Lillian L.;
Patnaik, Amita;
Papadopoulos, Kyriakos P.;
De Bono, Johann S.;
Tolcher, Anthony W.;
Minton, Susan

Publication type:

Article

A Randomized Phase 2 Trial Comparing 3-Hour Versus 96-Hour Infusion Schedules of Paclitaxel for the Treatment of Metastatic Breast Cancer.

Published in:

Cancer (0008543X), 2010, v. 116, n. 4, p. 814, doi. 10.1002/cncr.24870

By:

Moulder, Stacy L.;
Holmes, Frankie A.;
Tolcher, Anthony W.;
Thall, Peter;
Broglio, Kristine;
Valero, Vicente;
Buzdar, Aman U.;
Arbuck, Susan G.;
Seidman, Andrew;
Hortobagyi, Gabriel N.

Publication type:

Article

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.

Published in:

2003

By:

Tolcher, A W;
Gerson, S L;
Denis, L;
Geyer, C;
Hammond, L A;
Patnaik, A;
Goetz, A D;
Schwartz, G;
Edwards, T;
Reyderman, L;
Statkevich, P;
Cutler, D L;
Rowinsky, E K

Publication type:

journal article

Case report and summary of literature: giant perineal keloids treated with post-excisional radiotherapy.

Published in:

BMC Dermatology, 2006, v. 6, p. 7, doi. 10.1186/1471-5945-6-7

By:

Jones, Kristin;
Fuller, Clifton D.;
Luh, Join Y.;
Childs, Craig C.;
Miller, Alexander R.;
Tolcher, Anthony W.;
Herman, Terence S.;
Thomas Jr, Charles R.

Publication type:

Article

Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 380, doi. 10.1007/s10637-022-01326-3

By:

Stathis, Anastasios;
Tolcher, Anthony W.;
Wang, Judy S.;
Renouf, Daniel J.;
Chen, Lin-Chi;
Suttner, Leah H.;
Freshwater, Tomoko;
Webber, Andrea L.;
Nayak, Tapan;
Siu, Lillian L.

Publication type:

Article

First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 586, doi. 10.1007/s10637-022-01217-7

By:

Berlin, Jordan;
Tolcher, Anthony W.;
Ding, Cliff;
Whisenant, Jennifer G.;
Horak, Ivan D.;
Wood, Debra L.;
Nadler, Paul I.;
Hansen, Ulla Holm;
Lantto, Johan;
Skartved, Niels Jørgen Ø.;
Pedersen, Mikkel W.;
Patnaik, Amita

Publication type:

Article

A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.

Published in:

Investigational New Drugs, 2020, v. 38, n. 5, p. 1483, doi. 10.1007/s10637-020-00908-3

By:

Cleary, James M.;
Calvo, Emiliano;
Moreno, Victor;
Juric, Dejan;
Shapiro, Geoffrey I.;
Vanderwal, Carol Ann;
Hu, Beibei;
Gifford, Maryella;
Barch, David;
Roberts-Rapp, Lisa;
Ansell, Peter J.;
Xiong, Hao;
Ocampo, Christopher;
Tolcher, Anthony W.

Publication type:

Article

A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors.

Published in:

Investigational New Drugs, 2020, v. 38, n. 1, p. 120, doi. 10.1007/s10637-019-00754-y

By:

Rosen, Lee S.;
Wesolowski, Robert;
Baffa, Raffaele;
Liao, Kai-Hsin;
Hua, Steven Y.;
Gibson, Brenda L.;
Pirie-Shepherd, Steven;
Tolcher, Anthony W.

Publication type:

Article

Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 629, doi. 10.1007/s10637-017-0532-2

By:

Goldman, Jonathan W.;
Rosen, Lee S.;
Tolcher, Anthony W.;
Papadopoulos, Kyriakos;
Beeram, Muralidhar;
Shi, Peipei;
Pitou, Celine;
Bell, Robert;
Kulanthaivel, Palaniappan;
Zhang, Xuekui;
Fink, Aaron;
Chan, Edward M.;
Shahir, Ashwin;
Farrington, Daphne;
Patnaik, Amita

Publication type:

Article